Table 3.
Change in diagnosis following [18F]flutemetamol PET
| Initial diagnosis | Change | [18F]Flutemetamol PETa | Number (%) of those with change | Diagnosis after [18F]flutemetamol PET |
|---|---|---|---|---|
| MCI | 67/131 (51%) | Positive | 58 (87%) | 1 non-AD (DLB), 13 prodromal AD, 44 AD |
| Negative | 9(13%) | 1 AD, 3 dementia NOS, 5 non-AD (4 VaD, 1 PSP) | ||
| AD | 8/41 (20%) | Positive | 1 (12.5%) | Non-AD (DLB) |
| Negative | 7 (87.5%) | 1 dementia NOS, 2 non-AD (DLB, FTD), 4 MCI | ||
| Non-AD | 3/10 (30%)b | Positive | 2 (67%) | AD |
| Negative | 1 (33%) | MCI | ||
| Dementia NOS | 11/20 (55%) | Positive | 4 (36%) | AD |
| Negative | 7 (64%) | Non-AD (1 DLB, 3 VaD, 3 FTD) | ||
| SCD | 3/5 (60%) | Positive | 3 (100%) | MCI, prodromal AD, AD |
| Negative | – | – |
DLB dementia with Lewy bodies, FTD frontotemporal dementia, PSP progressive supranuclear palsy, VaD vascular dementia
a[18F]Flutemetamol PET status (positive/negative) was based on visual assessment supported by SUVR findings
bIn two non-AD patients with DLB the initial diagnosis was FTD